-+ 0.00%
-+ 0.00%
-+ 0.00%

Revvity Expects 2026 Pro Forma Revenue of About $2.9 Billion

PUBT·11/13/2026 15:15:04
Revvity Expects 2026 Pro Forma Revenue of About $2.9 Billion
  • Revvity projects 2026 revenue of approximately $2.9 billion in its November 13 investor presentation, reflecting guidance issued November 3.
  • Life Sciences revenue is forecast at approximately $1.5 billion, with Diagnostics contributing approximately $1.4 billion.
  • Recurring revenue is expected to account for approximately 85% of total revenue.
  • The outlook excludes the China immunodiagnostics business, which is under a definitive agreement to be divested.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.